Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Aggression × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 40 Leukemia, Myeloid, Acute 19 Recurrence 18 Lymphoma, Large B-Cell, Diffuse 10 Sarcoma 8 Neoplasms, Plasma Cell 5 Glioblastoma 5 Neurofibrosarcoma 4 Neoplasms 4 Lymphoma, T-Cell, Peripheral 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Myelodysplastic Syndromes 3 Lymphoma, B-Cell 3 Liposarcoma 3 Glioma 3 Waldenstrom Macroglobulinemia 2 Thymoma 2 Sarcoma, Alveolar Soft Part 2 Rhabdoid Tumor 2 Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Mantle-Cell 2 Leukemia, Myelomonocytic, Chronic 2

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 glofitamab 1 Topotecan 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡